News | June 15, 2008

SNM Image of the Year: Molecular Imaging, From Head to Toe

June 16, 2008 - From the top of the head to the soles of the feet, molecular imaging is a vital element of today's medical practice, adding an extra dimension to diagnosis and disease management that can change the way common and devastating diseases are understood and treated.

"Molecular imaging is making major scientific contributions by improving health care through prevention, diagnosis, treatment planning, treatment monitoring and disease recurrence assessment. These are the ‘big five' functions of molecular imaging," said Henry N. Wagner Jr., SNM past president and professor at Johns Hopkins University Bloomberg School of Public Health, who annually selects the SNM Image of the Year from thousands presented at the Annual Meeting.

This year, two images were jointly selected as the 2008 SNM Image of the Year. One image reveals a relapse of neuroendocrine cancer—a malignancy of the interface between the hormonal and nervous systems—including a nodal involvement. The second image illustrates the exact extent and location of an infection in the foot.

These two images were united not only to demonstrate the breadth and depth of molecular imaging but also to show that imaging techniques are increasingly being used in combination to provide precise snapshots of both the molecular function and the anatomy of disease in various parts of the human body.

"Using positron emission tomography and computed tomography (PET/CT), one group of physicians was able to see that a suspicious lesion in the left ear was not confined just to that area, but also involved a lymph node. This helped them plan the subsequent treatment," added Dr. Wagner. "The image of the foot shows that single photon emission computed tomography with magnetic resonance imaging (SPECT/MRI) is being used just as successfully as PET/CT. In this one, the fused image shows clearly that the patient has not only a soft tissue infection but also osteomyelitis—or infection of bone or bone marrow."

The first image comes from a case of a neuroendocrine tumor located in the left middle ear that was referred for restaging. "The patient was a young male treated by surgery a few months before," said Stefano Fanti, professor of nuclear medicine at the Policlinico S. Orsola–Università di Bologna in Italy. "Conventional imaging, including CT and MR, showed a suspect local relapse. PET/CT confirmed the local relapse, but also demonstrated a nodal involvement, leading to an alteration of his treatment. The finding was subsequently confirmed by CT, and the patient was scheduled for systemic treatment."

The second image reveals an abnormal cellular process in the infected foot of a diabetic patient. "MRI provides almost perfect images of anatomy and bony structure changes, but it may exaggerate the extent of infection," said Karin Knesaurek, associate professor in the department of radiology and nuclear medicine at Mount Sinai Medical School. "SPECT imaging is more accurate for infection localization but lacks anatomical reference. By combining these, we were able to determine the exact extent and location of the disease, and the patient underwent selective excision of the second metatarsal head only, preserving the rest of her foot."

Dr. Fanti and Dr. Knesaurek presented their work at the SNM 55th Annual Meeting, "Molecular Imaging: Build on the Past, Define the Future," which was attended by thousands of molecular imaging scientists and technologists. The meeting showcased molecular imaging's ability to provide a portrait of what's going on in a patient's body, providing useful information to help shape treatment plans, often eliminating the need for exploratory surgery and providing a painless and safe alternative for diagnosing and treating patients. It also allows doctors to see how effective a treatment is early in the process, so that it can be immediately adjusted.

"These images represent the present state-of-the-art and show that molecular imaging modalities such as SPECT and PET are here to stay," said Dr. Wagner.

Posters: S. Fanti, P. Castellucci, V. Ambrosini, P. Tomassetti, G. Montini, V. Allegri, D. Rubello, C. Nanni, R. Franchi, Nuclear Medicine, Azienda Ospedialiero-Universitaria di Bologna, Bologna, Italy, "Restaging of Neuroendocrine Tumor Imaged with 68GA-DOTA-NOC PET-CT." K. Knesaurek, J. Machac, M. Muzinic, M. DaCosta, Z. Zhang, B. Mocherla, S. Heiba, Department of Radiology/Nuclear Medicine; D. Kolker, Department of Orthopedics; and S. Vatti, Department of Radiology/MSK all at Mount Sinai Medical School, New York, N.Y. "Fusion of In-111 WBC SPECT/CT and MRI in a Diabetic Patient With an Infected Foot," SNM 55th Annual Meeting, June 14–18, 2008.

For more information: www.snm.org

Related Content

Videos | SPECT-CT | December 12, 2018
This is a walk around of the new Spectrum Dynamics Veriton SPECT-CT nuclear imaging system introduced at the 2018 ...
Spectrum Dynamics Sues GE for Theft, Misappropriation of Trade Secrets and Unfair Competition
News | SPECT Imaging | December 06, 2018
Single-photon emission computed tomography (SPECT) cardiac imaging company Spectrum Dynamics filed a lawsuit Dec. 6,...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Cardiac MRI being performed at the DeBakey Heart Hospital.

Cardiac MRI being performed at the DeBakey Heart Hospital.

Feature | Cardiac Imaging | May 03, 2018 | By Jeff Zagoudis
Magnetic resonance imaging (MRI) for cardiac assessment provides a radiation-free alternative to other commonly used...
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
Videos | Nuclear Imaging | August 24, 2017
Prem Soman, M.D., director of nuclear cardiology at the Heart and Vascular Institute, University of Pittsburgh, and p
GE Healthcare SPECT/CT and PET/CT Systems Enhance Personalized Patient Care
News | Nuclear Imaging | June 10, 2017
GE Healthcare showcased positron emission tomography (PET) and single photon emission computed tomography/computed...
advanced visualization
News | Molecular Imaging | June 09, 2017
The Food and Drug Administration (FDA) has cleared syngo.via VB20 for Molecular Imaging (MI) from Siemens Healthineers...